| Literature DB >> 36239793 |
Thomas Kiefer1,2, Christian Lüders3, Heinz Völler3,4, Georg Daeschlein5.
Abstract
OBJECTIVE: Because immunocompromised patients are particularly vulnerable during the SARS-CoV-2 pandemic, patients undergoing high-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (HDC/alloSCT) face the question of whether they should enter a rehabilitation stay. We therefore asked to what extent the pandemic has changed the acceptance of a rehabilitation stay and whether and how high the risk of infection for these patients should be assessed.Entities:
Keywords: Allogeneic; Immunosuppression; Rehabilitation; SARS-CoV-2 pandemic; Stem cell transplantation
Year: 2022 PMID: 36239793 PMCID: PMC9561317 DOI: 10.1007/s00432-022-04403-5
Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN: 0171-5216 Impact factor: 4.322
Patient characteristics
| Number of rehabilitation stays | 75 |
| Age (median) | 58.5 |
| Women/men (%) | 38/37 (50.7/49.3) |
| Time between HDC/alloSCT and start of rehabilitation stay (days; median, range) | 236 (48–1154) |
| Number of patients with immunosuppression during the rehabilitation stay (%) | 38 (50.79) |
| Diseases | |
| Acute myelogenous/lymphatic leukemia (de novo and secondary) | 42 |
| Myelodysplastic syndrome | 12 |
| Non-Hodgkin lymphoma (B and T cells) | 10 |
| Myeloproliferative disorders | 8 |
| Hodgkin disease (relapse) | 1 |
| Aplastic anemia | 1 |
| Wiskott–Aldrich syndrome | 1 |
HDC/alloSCT high-dosage chemotherapy with allogeneic hematopoietic stem cell transplantation
Fig. 1Number of patients with rehabilitation stay after HDC/alloSCT, †between 01 Jan 2019 and 14 March 2020 calculated on 12 months, ‡between 15 March 2020 and 30 June 2022 calculated on 12 months, *p < 0.05. Graphic done by Excel, Windows
Differences in patients before and during the SARS-CoV-2 pandemic
| Before† SARS-CoV-2 pandemic | After‡ SARS-CoV-2 pandemic | Significance | |
|---|---|---|---|
| Number of patients | 43 | 32 | |
| Patients with immunosuppressive medication | 28 | 10 | |
| Temporal distance between allogeneic transplantation and the start of the rehabilitation stay (days, median) | 159 | 311 | |
| HADS anxiety score (median) | 6.72 | 4.78 | |
| Platelet count (median) | 147 | 213 | |
| Age, sex, leukocyte count, absolute neutrophil count, hemoglobin level, renal function, C-reactive protein, medication with antiviral, antibiotic, or antifungal, body mass index, HADS depression score, ever suffered from graft-versus-host disease | n.s |
n.s. not significance, HADS hospital anxiety and depression scale
†Between 01 Jan 2019 and 14 March 2020
‡Between 15 March 2020 and 30 June 2022